NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/21/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization25.41 mln
Float30.54 mln
Earnings Date08/14/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.68
Likely reliable
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-64.05
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
VYNE Therapeutics is a clinical-stage company working to develop new treatments for chronic inflammatory and immune-related diseases. Its two main programs include a topical gel and an oral medicine, both designed to target the biological pathways that drive inflammation while minimizing side effects throughout the body. Founded in 2003 and based in Stewartsville, New Jersey, the company was previously known as Menlo Therapeutics before adopting its current name in 2020.
